Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 30

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 30
---
,000(equity or equity linked instruments including all applicable social security contributions) for the compensation of members of the Board of Directors; and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2 Approval of the Compensation for the Executive Officers Explanation:In connection with the Merger and the renewal of the senior management of the Company, the Company proposes that the previously approved compensation for the executive officers be adjusted. The Board of Directors believes that the newly proposed compensation for the executive officers adequately reflects their respective efforts on behalf of the Company. Proposal:The Board of Directors proposes: (i) to approve the new maximum aggregate amount of CHF 494,000 (cash compensation including all applicable social security contributions) for the fixed compensation of the Company’s executive officers, (ii) to approve the new maximum aggregate amount of CHF 2,206,000 (cash compensation including all applicable social security contributions) for the variable compensation of the Company’s executive officers, (iii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF991,000 (equity or equity linked instruments including all applicable social security contributions) for the Company’s executive officers, and (iv) to approve the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of the financial year 2025 and the financial year 2026. 13.Approval of Contingent Value Rights (CVR) Agreement on an Advisory Basis Explanation:The Company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset, as part of a contingent value rights agreement (the “CVR Agreement”). The combined company intends to develop the DOXA R&D asset, which will remain with the combined company (both independently and in combination with the company’s diabetes product). The remaining assets of the Company are intended to be reorganized under the CVR Agreement for the purpose of being sold by a committee to be established specifically for this purpose and responsible for executing the sale. Shareholders of the Company, as they exist prior to the